

## **ANNOUNCEMENT OF RESULTS**

The Company is based in Gerakas, Attica.

The Group is active in the fields of medical consumables and diagnostic centers.

The Group's sales, after the removal of rebates and claw back, amounted to € 18,375 million compared to 18,717 million in the corresponding period last year, decreased by 342 thousand and 1,83%.

The Group's EBIDTA decreased by 7,42% and amounted to €3,410 million compared to €3,683 million in 2023.

Earnings after taxes decreased by 7,56% and amounted to € 1,334 million compared with € 1,443 million in 2023.

The decrease in the above figures is mainly due to the performance of the Group's subsidiaries (Diagnostic Laboratories) and also to the sale of subsidiary.

Equity increased to 18,569 million from 17,720 million. The Group's solvency ratio (Net position as % of total assets excluding cash and term deposits) at 31/12/2024 was 80,84%.

The Group's borrowing amounts to € 8,406 million and relates exclusively to the parent company.

Regarding the financial figures of the parent company MEDICON HELLAS AE, the turnover amounted to € 16,962 million compared with € 16,671 million in the corresponding period last year, an increase of 1,74%.

The company's EBIDTA amounted to € 3,641 million against € 3,169 million in 2023 showing an increase of 14,89%.

Earnings after taxes amounted to € 1,792 million compared with € 1,092 million in 2023, marking an increase.

The increase in sizes for the parent company is due to the increase in turnover, the reduction in operating expenses and the reduction in financial expenses, in relation to the corresponding previous period.

<b>Summary Statement of Group Effective Use in mil.</b>		
	<b>2024</b>	<b>2023</b>
Total sales	18.375	18.717
Gross profit	13.039	13.415
Other operating income	172	335
Research and Sales Management expenses	-11.380	-11.690
Other expenses & losses	-171	-76
Profit before tax & investment	1.660	1.983
Financial income/expenses	-110	-310
Depreciation included in operating profit	1.749	1.700
Profit before tax	1.550	1.673
Taxes	-216	-229
Profit/(loss) after tax	<b>1.334</b>	<b>1.443</b>
Earnings per share	0,3091	0,2990

<b>Summary Group Balance Sheet in mil</b>		
	<b>2024</b>	<b>2023</b>
<b>ASSETS</b>		
<b>Non current assets</b>		
Self-used fixed fixtures	6.996	7.237
Intangible assets	48	65
Deferred tax assets	2.715	2.725
Other non-current receivables	32	69
<b>Current assets</b>		
Stocks	2.862	3.293
Requirements from customers	8.612	9.243
Other current receivables	1.705	3.864
Cash and cash equivalents	8.513	5.465
<b>TOTAL ASSETS</b>	<b>31.484</b>	<b>31.960</b>
<b>EQUITY</b>		
<b>EQUITY &amp; LIABILITIES</b>		
Own funds	18.569	17.720
Long-term bank liabilities	7.794	8.843
Other non-current liabilities	1.171	1.226
Current bank liabilities	612	552
Suppliers and other liabilities	3.338	3.619
<b>TOTAL EQUITY &amp; LIABILITIES</b>	<b>31.484</b>	<b>31.960</b>